A population pharmacodynamic model characterizing neutropenia associated with pegylated interferon alpha 2-a therapy in patients with chronic hepatitis C viral infection-Reference-Cited by-同舟云学术

A population pharmacodynamic model characterizing neutropenia associated with pegylated interferon alpha 2-a therapy in patients with chronic hepatitis C viral infection

Published:2018-06-05 Issue:9 Volume:391 Page:953-963
ISSN:0028-1298
Container-title:Naunyn-Schmiedeberg's Archives of Pharmacology
language:en
Short-container-title:Naunyn-Schmiedeberg's Arch Pharmacol

Author:

Saleh Mohammad I.^ORCID,Hindi Nagham N.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,General Medicine

Link

http://link.springer.com/article/10.1007/s00210-018-1517-1/fulltext.html

Reference25 articles.

1. Alter MJ, Mast EE (1994) The epidemiology of viral hepatitis in the United States. Gastroenterol Clin N Am 23:437–455

2. Alzubiedi S, Saleh MI (2017) Predictors of severe thrombocytopenia secondary to peginterferon alfa-2a treatment in subjects with hepatitis C virus infection. Am J Ther 24(6):e670–e675

3. Bekkering FC, Neumann AU, Brouwer JT, Levi-Drummer RS, Schalm SW (2001) Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis C patients: a case control study. BMC Gastroenterol 1:14

4. Camma C, Giunta M, Andreone P, Craxi A (2001) Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 34:593–602

5. Dancey JT, Deubelbeiss KA, Harker LA, Finch CA (1976) Neutrophil kinetics in man. J Clin Invest 58:705–715

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of highly stable and de-immunized versions of recombinant alpha interferon: Promising candidates for the treatment of chronic and emerging viral diseases;Clinical Immunology;2021-12

2. A time-to-event analysis describing virologic response in patients with chronic hepatitis C infection;Journal of Chemotherapy;2019-05-09